Robert W. Baird analyst Jeff Johnson maintained a Buy rating on Henry Schein (NASDAQ:HSIC) on Tuesday, setting a price target of $94, which is approximately 24.47% above the present share price of $75.52.
Johnson expects Henry Schein to post earnings per share (EPS) of $1.11 for the fourth quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Henry Schein, with an average price target of $86.56.
The analysts price targets range from a high of $98 to a low of $72.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $2.97 billion and a net profit of $210.95 million. The company's market cap is $10.55 billion.
According to TipRanks.com, Robert W. Baird analyst Jeff Johnson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 31.1% and a 68.21% success rate.
Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial services on a non-recourse basis, e-services practice, technology, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.